bioAffinity Technologies

03/06/2026

Interventional pulmonology continues to evolve with robotics and advanced diagnostic tools, but deciding when to intervene remains one of the most important clinical decisions.

Vamsi Guda, DO, uses CyPath® Lung to risk-stratify patients with small pulmonary nodules before moving toward more advanced interventions. By providing additional insight into malignancy risk, the test helps clinicians decide when to proceed and when monitoring may be appropriate.

That clarity supports earlier detection, more confident decisions, and a care pathway that prioritizes both patient safety and clinical precision.

Learn more: https://www.cypathlung.com/

03/04/2026

Lung cancer workups often rely on imaging and biopsy, but many patients don’t meet size thresholds for those steps early on.

Israel Elias Garcia, MSN, uses CyPath® Lung to supplement the diagnostic process and help provide earlier insight into malignancy risk and prognosis. The noninvasive, at-home collection process supports participation, while timely results help clinicians address patient questions and plan care with greater clarity.

By bringing patients into the decision-making process earlier, tools like CyPath® Lung support more informed conversations about monitoring, treatment planning, and next steps.

Learn more: https://www.cypathlung.com/

03/03/2026

New data presented at the American Academy of Allergy, Asthma, and Immunology 2026 annual meeting by our Chief Science Officer, William Bauta, PhD, highlights the ability of our innovative diagnostic approach to identify antibody drug receptors in sputum, including receptors for dupilumab, a leading therapy for asthma and COPD, and benralizumab, another asthma therapy.

Asthma and COPD impact approximately 650 million children and adults globally and many patients must try a series of therapies before finding one that works well for them.

We are leveraging our expertise in using our proprietary flow cytometry platform equipped with automated AI analysis to develop tests that match asthma and COPD patients with the most appropriate biologic therapies and monitor their ongoing conditions.

Read more about the new scientific poster presentation: https://bit.ly/4cYPt4f

02/26/2026

For pulmonologist Greg White, M.D. early lung cancer detection is only part of the challenge. The next step is deciding what to do when a nodule is found.

With a growing number of CT scans and more nodules to evaluate, Dr. White relies on CyPath® Lung to help risk stratify patients and inform whether to continue surveillance or move toward biopsy.

Clarity is critical in clinical environments where every decision affects both patient experience and outcomes. Learn more about the difference CyPath® Lung is making in noninvasive, early lung cancer diagnostics. https://cypathlung.com

02/25/2026

bioAffinity Technologies (Nasdaq: BIAF) announces a new study with Brooke Army Medical Center (BAMC) to validate the use of CyPath® Lung with sputum samples collected via tracheal and bronchial suction during routine clinical procedures.

The study is designed to assess whether samples collected during routine airway procedures may expand clinical utility for early lung cancer detection in high-risk patients.

Enrollment is expected to include 30–50 patients, with results anticipated mid-2026.

We look forward to advancing noninvasive approaches to earlier detection.

Read the full announcement: https://bit.ly/4cL7bbg

02/24/2026

Early detection can make all the difference in lung cancer, but indeterminate nodules often leave patients and clinicians waiting for clarity.

CyPath® Lung is a noninvasive test designed to support early insight for high-risk patients by analyzing the lung microenvironment and informing next steps in care.

Know More. Move Forward. https://www.cypathlung.com

02/19/2026

A new clinical case study from bioAffinity Technologies highlights how CyPath® Lung supported a recommendation for surveillance rather than subjecting an elderly, high-risk patient to an invasive biopsy after a suspicious lung nodule was identified.

The noninvasive test provided objective data to help guide clinical decision-making and support a conservative management approach. A follow-up scan later showed no pulmonary nodules, reinforcing the surveillance strategy.

Read the full case study: https://bit.ly/40iYHkd

02/17/2026

Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment of benign pulmonary nodules.

This data supports evidence-based surveillance decisions, reinforces guideline-consistent follow-up intervals and may help reduce invasive procedures on benign nodules. Read the findings: https://bit.ly/4sgkuoX

02/12/2026

When a pulmonary nodule is identified, clinicians must balance speed, accuracy, and patient experience as next steps are determined.

Daya Nadarajah, M.D. points to CyPath® Lung for its ability to detect lung cancer early and noninvasively.

The practical turnaround time gives physicians more information and minimizes the added burden on patients who are navigating uncertainty.

CyPath® Lung helps assess malignancy risk without invasive procedures and supports more informed decisions so physicians can move forward with greater clarity.

02/11/2026

Lung cancer remains the leading cause of cancer-related death, largely because it is often diagnosed at a late stage. In a recent interview, bioAffinity Technologies CEO Maria Zannes explains how identifying lung cancer at stage 1 can significantly improve long-term survival.

She discusses how CyPath® Lung fits into the clinical pathway after indeterminate pulmonary nodules are detected through imaging, offering a noninvasive way to assess malignancy risk. The conversation also explores how this approach can help reduce uncertainty for both physicians and patients.

Watch the full Smart Money Circle Show interview:

This Biotech CEO Wants To Cure Lung Cancer – Maria Zanes President & CEO bioAffinity Technologies BIAF Ticker: BIAF Websitehttps://bioaffinitytech.com/Maria ...

02/09/2026

bioAffinity Technologies (Nasdaq: BIAF) is expanding its Medical and Scientific Advisory Board with the appointment of nationally recognized leaders in pulmonary medicine and lung cancer care.

Drs. David Ost, Daniel Sterman and J. Scott Ferguson join the board as the company expands adoption of CyPath® Lung, its noninvasive diagnostic designed to support earlier detection of lung cancer, particularly in patients with indeterminate pulmonary nodules.

Read the full announcement: https://bit.ly/3OvR1Zb